Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Navidea Biopharmaceuticals Company Profile (NASDAQ:NAVB)

Consensus Ratings for Navidea Biopharmaceuticals (NASDAQ:NAVB) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $2.58 (95.08% upside)

Analysts' Ratings History for Navidea Biopharmaceuticals (NASDAQ:NAVB)
Show:
DateFirmActionRatingPrice TargetDetailsShare
5/19/2014JMP SecuritiesReiterated RatingOutperform$5.00 -> $3.00ViewTweet This Rating  Share This Rating on StockTwits
3/11/2014ZacksDowngradeNeutral$2.30ViewTweet This Rating  Share This Rating on StockTwits
11/13/2013AegisReiterated RatingHold$3.00 -> $2.00ViewTweet This Rating  Share This Rating on StockTwits
11/7/2013Ladenburg ThalmannLower Price TargetBuy$7.50 -> $3.00ViewTweet This Rating  Share This Rating on StockTwits
4/9/2013Janney Montgomery ScottInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
3/5/2013Piper JaffrayInitiated CoverageUnderweight$1.50ViewTweet This Rating  Share This Rating on StockTwits
1/22/2013AegisInitiated CoverageHold$3.00ViewTweet This Rating  Share This Rating on StockTwits
1/22/2013Burrill Institutional ResearchInitiated CoverageOutperform$5.00ViewTweet This Rating  Share This Rating on StockTwits
11/27/2012Dawson JamesInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
9/11/2012WBB SecuritiesLower Price TargetStrong-Buy$9.00 -> $7.00ViewTweet This Rating  Share This Rating on StockTwits
9/11/2012ThinkEquityDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
9/11/2012Ladenburg ThalmannBoost Price TargetBuy$6.25 -> $7.50ViewTweet This Rating  Share This Rating on StockTwits
9/11/2012Rodman & RenshawLower Price TargetOutperform$7.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2012 forward)